Genmab — Juli 2025
-
Phase III trial of rinatabart sesutecan in platinum-resistant ovarian cancer https://www.youtube.com/watch?v=JSXmQpDA71M 'we are thrilled to have the opportunity to offer this trial to our patients because this response rate is so much higher than what we see typically in this patient population
, where SOC range from 15-30%' -
Genmab A/S (GMAB) PT Raised to $46; Truist: 'This Stock Deserves More Appreciation' https://www.streetinsider.com/Analyst+Comments/Genmab+AS+(GMAB)+PT+Raised+to+%2446%3B+Truist%3A+This+Stock+Deserves+More+Appreciation/25025147.html
-
Genmab spås højt potentiale hos børshus: Nuværende værdiansættelse "yder liden retfærdighed https://proinvestor.com/investornyt/1337145/genmab-spas-hojt-potentiale-hos-borshus-nuvaerende-vaerdiansaettelse-yder-liden-retfaerdighed
-
again, GEN1057 moves expected
completion dates a year earlier.... https://clinicaltrials.gov/study/NCT06573294?tab=history&a=9&b=10&compareMode=sideBySide#version-content-panel -
the Acasunlimab Melanoma trial starts to recruit https://clinicaltrials.gov/study/NCT06984328?tab=history&a=2&b=3#version-content-panel
-
- jul. 2025
Biotekselskab springer op: Finanshuse ser stort potentiale https://www.euroinvestor.dk/nyheder/biotekselskab-springer-op-finanshuse-ser-stort-potentiale?referrer=RSS
- jul. 2025
-
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial https://www.tandfonline.com/doi/full/10.1080/10428194.2025.2525983#abstract
-
-
Juli-stilhed på de sociale aktiemedier, usikkerhed efter nye meldinger fra Trump om toldsatser, Bavarian Nordic lander stor ordre. Genmab-aktien er steget. Zealand Pharma, Novo Nordisk og Gubra er derimod faldet i kurs. Det er temaerne, som Helge Larsen dykker ned i i denne korte ugevideo.
https://proinvestor.com/boards/127162 -
Trump-regering og medicinalkæmper gør klar til stort slagsmål https://proinvestor.com/investornyt/1338847/trump-regering-og-medicinalkaemper-gor-klar-til-stort-slagsmal
-
Genmab er dagens aktie hoske JB. Konlusion: "Vi forventer ikke, at aktien laver en skyder i vejret, men derimod langsomt genvinder markedets tiltro – en overvindelse er i gang og aktiens er steget ca. 15% fra bunden i april." https://www.jyskebank.dk/finansnyt/morgennyt/bd9538fa-0801-43ec-9f26-2f40e1190fcf/!ut/p/z1/rVRdc6owEP0tffCRyfIVoG_4cZUiVaxWyIuDGGgsAQto67-_UeZOrdPW3ql5SXaze_ZkZ08QQQEiebRjaVSzIo8yYYcEL8ZKV5PNB7jvj9sq-NOh-2fSncjTkYEeUdhG4a4Fg_XWR_NL4URcwxfLBnR3DFD6uP_Y0U3PsNw2OL2pI2PHhaEpH_g
-
EPCORE DLBCL-3 seems to be ready recruiting at 111 instead of 180 patients https://clinicaltrials.gov/study/NCT05660967?tab=history&a=37&b=38#version-content-panel
rart med lidt medvind endda på kursen også..Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind